Stuart Arbuckle

Stuart A. Arbuckle joined Vertex in September 2012. As Vertex’s Executive Vice President and Chief Commercial Officer, Mr. Arbuckle oversees Vertex’s global commercial team, which is responsible for the company’s sales, marketing, patient support, market research and other activities that support the approved use of Vertex’s two medicines.

Mr. Arbuckle has more than 25 years of experience in leading global sales and marketing efforts at biopharmaceutical companies. Prior to joining Vertex, Mr. Arbuckle held multiple commercial leadership roles at Amgen, Inc., a 17,000-person biotechnology company. As Vice President and General Manager, Oncology Business Unit, he led sales, marketing, patient advocacy and access efforts for Amgen’s portfolio of cancer medicines. He was responsible for sales and marketing efforts for Aranesp®, Neulasta® and NEUPOGEN®, which accounted for more than $5 billion in sales in 2011, and led the successful launches of XGEVA® and Nplate®. Most recently, he served as Vice President and Regional General Manager where he led efforts to expand Amgen's presence in Japan and emerging markets in Asia, the Middle East and Africa.

Prior to these roles, Mr. Arbuckle spent more than 15 years at GlaxoSmithKline (GSK) plc, where he held sales and marketing roles of increasing responsibility for medicines aimed at treating respiratory, metabolic, musculoskeletal, cardiovascular and other diseases. He joined GSK after earning a degree in pharmacology and physiology from the University of Leeds in the United Kingdom. Mr. Arbuckle currently serves as a national board member of the Cancer Support Community, an international non-profit dedicated to providing support, education and hope to people affected by cancer, and on the Health Section Governing Board for the Biotechnology Industry Organization.